Vol 2, No 3 (2017)
REVIEW ARTICLE
Published online: 2017-10-20
Iodine-induced thyroid disorders in the practice of a cardiologist
Disaster Emerg Med J 2017;2(3):120-124.
Abstract
This article deals with the question of the influence of preparations that contain pharmacological doses of iodine on the functional activity of the thyroid gland. In the practice of a cardiologist amiodarone and x-ray contrasting substances are often used that may induce thyroid disorders in many ways, followed by hypothyroidism and thyrotoxicosis development.
Keywords: iodinethyroid dysfunctionamiodarone
References
- Bartalena L, Wiersinga WM, Tanda ML, et al. Diagnosis and management of amiodarone-induced thyrotoxicosis in Europe: results of an international survey among members of the European Thyroid Association. Clin Endocrinol (Oxf). 2004; 61(4): 494–502.
- Basaria S, Cooper DS. Amiodarone and the thyroid. Am J Med. 2005; 118(7): 706–714.
- Batcher EL, Tang XC, Singh BN, et al. Thyroid function abnormalities during amiodarone therapy for persistent atrial fibrillation. Am J Med. 2007; 120(10): 880–885.
- Bogazzi F, Bartalena L, Dell'Unto E, et al. Proportion of type 1 and type 2 amiodarone-induced thyrotoxicosis has changed over a 27-year period in Italy. Clin Endocrinol (Oxf). 2007; 67(4): 533–537.
- Camargo RYA, Tomimori EK, Neves SC, et al. Thyroid and the environment: exposure to excessive nutritional iodine increases the prevalence of thyroid disorders in Sao Paulo, Brazil. Eur J Endocrinol. 2008; 159(3): 293–299.
- Cohen-Lehman J, Dahl P, Danzi S, et al. Effects of amiodarone therapy on thyroid function. Nat Rev Endocrinol. 2010; 6(1): 34–41.
- Col NF, Surks MI, Daniels GH. Subclinical thyroid disease: clinical applications. JAMA. 2004; 291(2): 239–243.
- Daniels GH. Amiodarone-induced thyrotoxicosis. J Clin Endocrinol Metab. 2001; 86(1): 3–8.
- Dietlein M, Schicha H. Amiodarone-induced thyrotoxicosis due to destructive thyroiditis: therapeutic recommendations. Exp Clin Endocrinol Diabetes. 2005; 113(3): 145–151.
- Duntas LH. Subclinical thyroid disorders: the menace of the Trojan horse. J Endocrinol Invest. 2003; 26(5): 472–480.
- Eskes SA, Wiersinga WM. Amiodarone and thyroid. Best Pract Res Clin Endocrinol Metab. 2009; 23(6): 735–751.
- Franklyn JA, Sheppard MC, Maisonneuve P. Thyroid function and mortality in patients treated for hyperthyroidism. JAMA. 2005; 294(1): 71–80.
- Fricke E, Fricke H, Esdorn E, et al. Scintigraphy for risk stratification of iodine-induced thyrotoxicosis in patients receiving contrast agent for coronary angiography: a prospective study of patients with low thyrotropin. J Clin Endocrinol Metab. 2004; 89(12): 6092–6096.
- Haentjens P, Van Meerhaeghe A, Poppe K, et al. Subclinical thyroid dysfunction and mortality: an estimate of relative and absolute excess all-cause mortality based on time-to-event data from cohort studies. Eur J Endocrinol. 2008; 159(3): 329–341.
- Hak AE, Pols HA, Visser TJ, et al. Subclinical hypothyroidism is an independent risk factor for atherosclerosis and myocardial infarction in elderly women: the Rotterdam Study. Ann Intern Med. 2000; 132(4): 270–278.
- Gharib H, Tuttle RM, Baskin HJ, et al. Subclinical thyroid dysfunction: a joint statement on management from the American Association of Clinical Endocrinologists, the American Thyroid Association, and the Endocrine Society. Endocr Pract. 2004; 10(6): 497–501.
- Goldschlager N, Epstein AE, Naccarelli GV, et al. Practical guidelines for clinicians who treat patients with amiodarone. Practice Guidelines Subcommittee, North American Society of Pacing and Electrophysiology. Arch Intern Med. 2000; 160(12): 1741–1748.
- Kahaly G, Dietlein M, Gartner R, et al. Amiodaron und Schilddrusendysfunktion. Deutsches Arzteblatt. 2007; 104(51–52): 3550–3555.
- Klein I, Danzi S. Thyroid disease and the heart. Circulation. 2007; 116(15): 1725–1735.
- Leung AM, Braverman LE. Iodine-induced thyroid dysfunction. Curr Opin Endocrinol Diabetes Obes. 2012; 19(5): 414–419.
- Markou K, Georgopoulos N, Kyriazopoulou V, et al. Iodine-Induced Hypothyroidism. Thyroid. 2001; 11(5): 501–510.
- Martino E, Bartalena L, Bogazzi F, et al. The effects of amiodarone on the thyroid. Endocr Rev. 2001; 22(2): 240–254.
- Meurisse M, Gollogly L, Degauque C, et al. Iatrogenic thyrotoxicosis: causal circumstances, pathophysiology, and principles of treatment-review of the literature. World J Surg. 2000; 24(11): 1377–1385.
- Muller AF, Berghout A, Wiersinga WM, et al. working group Thyroid Function Disorders of the Netherlands Association of Internal Medicine. Thyroid function disorders--Guidelines of the Netherlands Association of Internal Medicine. Neth J Med. 2008; 66(3): 134–142.
- Ochs N, Auer R, Bauer D, et al. Meta-analysis: Subclinical Thyroid Dysfunction and the Risk for Coronary Heart Disease and Mortality. Annals of Internal Medicine. 2008; 148(11): 832–845.
- Parle JV, Maisonneuve P, Sheppard MC, et al. Prediction of all-cause and cardiovascular mortality in elderly people from one low serum thyrotropin result: a 10-year cohort study. Lancet. 2001; 358(9285): 861–865.
- Piga M, Cocco MC, Serra A, et al. The usefulness of 99mTc-sestaMIBI thyroid scan in the differential diagnosis and management of amiodarone-induced thyrotoxicosis. Eur J Endocrinol. 2008; 159(4): 423–429.
- Sawin CT, Geller A, Wolf PA, et al. Low serum thyrotropin concentrations as a risk factor for atrial fibrillation in older persons. N Engl J Med. 1994; 331(19): 1249–1252.
- Tsang W, Houlden RL. Amiodarone-induced thyrotoxicosis: a review. Can J Cardiol. 2009; 25(7): 421–424.
- Ursella S, Testa A, Mazzone M, et al. Amiodarone-induced thyroid dysfunction in clinical practice. Eur Rev Med Pharmacol Sci. 2006; 10(5): 269–278.
- Walsh JP, Bremner AP, Bulsara MK, et al. Subclinical thyroid dysfunction as a risk factor for cardiovascular disease. Arch Intern Med. 2005; 165(21): 2467–2472.
- Yiu KH, Jim MH, Siu CW, et al. Amiodarone-induced thyrotoxicosis is a predictor of adverse cardiovascular outcome. J Clin Endocrinol Metab. 2009; 94(1): 109–114.